The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex that plays a vital role in the growth of KRAS-mutated lung cancers.

Researchers at the University of Seville have participated in the discovery of new chemical markers that regulate the activity of pyruvate kinase, opening the door to a better understanding of the metabolic reprogramming of cancer cells.

Highlights

•

Epithelial-mesenchymal transition (EMT) is a mechanism of chemoresistance.

•

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) use can trigger EMT and EMT can consequently confers resistance.

•

EGFR-TKI use alters protein or miRNA expression or activity, promoting EMT.

•

EMT is associated with altered effector protein expression, leading to resistance.

Washington, D.C. | 22 January 2026 – Sujuan Ba, CEO of the National Foundation for Cancer Research (NFCR), has been named to OncoDaily’s list of the 100 Most Influential CEOs in Oncology in 2025, recognizing leaders whose work is shaping the global cancer research and care ecosystem.

Researchers at Moffitt Cancer Center have developed a new way to predict how cancer cells evolve by gaining and losing whole chromosomes, changes that help tumors grow, adapt and resist treatment. In a study published in Nature Communications, scientists describe a computational approach called ALFA-K that uses longitudinal, single-cell data to reconstruct how cancer cells move through different chromosome states over time and identify which configurations are favored by evolution.

Cancer vaccine may offer new prevention strategy for patients with Lynch syndrome

Novel immunotherapy overcomes treatment resistance in multiple types of cancer

Engineered nanobodies improve respiratory defenses against multiple viruses

New combination treatments show promise for patients with early-stage Hodgkin lymphoma and breast cancer